The current state of breast cancer classification

Research output: Contribution to journalArticle

78 Citations (Scopus)

Abstract

Breast cancer is a highly heterogeneous disease due to its diverse morphological features, the variable clinical outcome and the response to different therapeutic options. It is therefore necessary to devise a clinically meaningful classification of the disease, which has to be scientifically sound, clinically useful and widely reproducible. The established histopathological classification has a limited clinical utility, due to insufficient prognostic and predictive power. More recent classification schemes, based on the immunohistochemical characterization of breast cancer for the assessment of hormone receptor status, HER2 gene over-expression or amplification and the proliferative fraction or on gene expression profiles, correlate much better with the clinical outcome and may be used to inform the choice of the systemic therapy.

Original languageEnglish
Article numbermds326
JournalAnnals of Oncology
Volume23
Issue numberSUPPL. 10
DOIs
Publication statusPublished - Sep 2012

Fingerprint

Breast Neoplasms
erbB-2 Genes
Gene Amplification
Transcriptome
Hormones
Gene Expression
Therapeutics

Keywords

  • Breast cancer
  • Classification
  • Immunohistochemistry
  • Molecular assays

ASJC Scopus subject areas

  • Oncology
  • Hematology

Cite this

The current state of breast cancer classification. / Viale, G.

In: Annals of Oncology, Vol. 23, No. SUPPL. 10, mds326, 09.2012.

Research output: Contribution to journalArticle

@article{3222bedee78943eba7eb7fda8d5f730a,
title = "The current state of breast cancer classification",
abstract = "Breast cancer is a highly heterogeneous disease due to its diverse morphological features, the variable clinical outcome and the response to different therapeutic options. It is therefore necessary to devise a clinically meaningful classification of the disease, which has to be scientifically sound, clinically useful and widely reproducible. The established histopathological classification has a limited clinical utility, due to insufficient prognostic and predictive power. More recent classification schemes, based on the immunohistochemical characterization of breast cancer for the assessment of hormone receptor status, HER2 gene over-expression or amplification and the proliferative fraction or on gene expression profiles, correlate much better with the clinical outcome and may be used to inform the choice of the systemic therapy.",
keywords = "Breast cancer, Classification, Immunohistochemistry, Molecular assays",
author = "G. Viale",
year = "2012",
month = "9",
doi = "10.1093/annonc/mds326",
language = "English",
volume = "23",
journal = "Annals of Oncology",
issn = "0923-7534",
publisher = "NLM (Medline)",
number = "SUPPL. 10",

}

TY - JOUR

T1 - The current state of breast cancer classification

AU - Viale, G.

PY - 2012/9

Y1 - 2012/9

N2 - Breast cancer is a highly heterogeneous disease due to its diverse morphological features, the variable clinical outcome and the response to different therapeutic options. It is therefore necessary to devise a clinically meaningful classification of the disease, which has to be scientifically sound, clinically useful and widely reproducible. The established histopathological classification has a limited clinical utility, due to insufficient prognostic and predictive power. More recent classification schemes, based on the immunohistochemical characterization of breast cancer for the assessment of hormone receptor status, HER2 gene over-expression or amplification and the proliferative fraction or on gene expression profiles, correlate much better with the clinical outcome and may be used to inform the choice of the systemic therapy.

AB - Breast cancer is a highly heterogeneous disease due to its diverse morphological features, the variable clinical outcome and the response to different therapeutic options. It is therefore necessary to devise a clinically meaningful classification of the disease, which has to be scientifically sound, clinically useful and widely reproducible. The established histopathological classification has a limited clinical utility, due to insufficient prognostic and predictive power. More recent classification schemes, based on the immunohistochemical characterization of breast cancer for the assessment of hormone receptor status, HER2 gene over-expression or amplification and the proliferative fraction or on gene expression profiles, correlate much better with the clinical outcome and may be used to inform the choice of the systemic therapy.

KW - Breast cancer

KW - Classification

KW - Immunohistochemistry

KW - Molecular assays

UR - http://www.scopus.com/inward/record.url?scp=84866765384&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84866765384&partnerID=8YFLogxK

U2 - 10.1093/annonc/mds326

DO - 10.1093/annonc/mds326

M3 - Article

C2 - 22987963

AN - SCOPUS:84866765384

VL - 23

JO - Annals of Oncology

JF - Annals of Oncology

SN - 0923-7534

IS - SUPPL. 10

M1 - mds326

ER -